Recent development in carbohydrate based anticancer vaccines

Journal of Carbohydrate Chemistry

Volumn 31, Issue 3, 2012, Pages 143-186

  Yin, Zhaojun ^a   Huang, Xuefei ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Anti cancer vaccine; Carbohydrate antigen; Glyco conjugates; Immune responses

Indexed keywords

ANIMALIA;

EID: 84859620289     PISSN: 07328303     EISSN: 15322327     Source Type: Journal    
DOI: 10.1080/07328303.2012.659364     Document Type: Article

References (160)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62, 10-29.
2. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
3. Coley, W.B. The classic-the treatment of malignant-tumors by repeated inoculations of erysipelas-with a report of 10 original cases. Clin. Orthop. Relat. Res. 1991, 262, 3-11.
4. Burnet, M. Cancer-a biological approach. Brit. Med. J. 1957, 1, 841-847.
5. Grillo-Lopez, A.J.; Hedrick, E.; Rashford, M.; Benyunes, M. Rituximab: ongoing and future clinical development. Semin. Oncol. 2002, 29, 105-112. (Pubitemid 34173032)
6. Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317-327.
7. Danishefsky, S.J.; Allen, J.R. From the laboratory to the clinic: a retrospective on fully synthetic carbohydrate-based anticancer vaccines. Angew. Chem. Int. Ed. 2000, 39, 836-863 and references cited therein. (Pubitemid 30217267)
8. Hakomori, S.; Zhang, Y. Glycosphingolipid antigens and cancer therapy. Chem. Biol. 1997, 4, 97-104. (Pubitemid 27161748)
9. Hakomori, S. Tumor malignancy defined by aberrant glycosylation and sphingo( glyco)lipid metabolism. Cancer Res. 1996, 56, 5309-5318. (Pubitemid 27011703)
10. Nores, G.A.; Dohi, T.; Taniguchi,M.; Hakomori, S. Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: requirements for tumor-associated antigen and immunogen. J. Immunol. 1987, 139, 3171-3176. (Pubitemid 17157496)
11. Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; Matrisian, L.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 2009, 15, 5323-5337.
12. Hakomori, S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 2001, 491, 369-402. (Pubitemid 32595136)
13. Livingston, P.O.; Zhang, S.; Lloyd, K.O. Carbohydrate vaccines that induce antibodies against cancer. 1. Rationale. Cancer Immunol. Immunother. 1997, 45, 1-9. (Pubitemid 27444464)
14. Hamilton, W.B.; Helling, F.; Lloyd, K.O.; Livingston, P.O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer 1993, 53, 566-573. (Pubitemid 23069265)
15. Huang, C.-Y.; Thayer, D.A.; Chang, A.Y.; Best, M.D.; Hoffmann, J.; Head, S.; Wong, C.H. Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc. Nat. Acad. Sci. USA 2006, 103, 15-20. (Pubitemid 43076097)
16. Kudryashov, V.; Glunz, P.W.; Williams, L.J.; Hintermann, S.; Danishefsky, S.J.; Lloyd, K.O. Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewisy conjugates in mice. Proc. Nat. Acad. Sci. USA 2001, 98, 3264-3268.
17. Zhou, B.B.; Zhang, H.; Damelin, M.; Geles, K.G.; Grindley, J.C.; Dirks, P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8, 806-23.
18. Lin, W.-M.; Karsten, U.; Goletz, S.; Cheng, R.-C.; Cao, Y. Co-expression of CD173 (H2) and CD174 (Lewis y) with CD44 suggests that fucosylated histo-blood group antigensare markers of breast cancer-initiating cells. VischowArch. 2010, 456, 403-409.
19. Chang, W.-W.; Lee, C.H.; Lee, P.; Lin, J.; Hsu, C.-W.; Hung, J.-T.; Lin, J.-J.; Yu, J.-C.; Shao, L.-e.; Yu, J.; Wong, C.-H.; Yu, A.L. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc. Natl. Acad. Sci. USA 2008, 105, 11667-11672.
20. Goldsby, R.A.; Kindt, T.J.; Osborne, B.A. B-cell Generation, Activation, and Differentiation. In Kuby Immunology; Freeman: New York, 2000, 275-285.
21. Bretscher, P.; Cohn, M. A theory of self-nonself discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 1970, 169, 1042-1049.
22. Livingston, P.O.;Wong, G.Y.C.; Adluri, S.; Tao, Y.; Padavan, M.; Parente, R.; Hanlon, C.; Calves, M.J.; Helling, F.; Ritter, G.; Oettgen, H.F.; Old, L.J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994, 12, 1036-1044. (Pubitemid 24145334)
23. Jones, P.C.; Sze, L.L.; Liu, P.Y.; Morton, D.L.; Irie, R.F. Prolonged survival for melanoma patients with elevated igm antibody to oncofetal antigen. J. Nat. Cancer Inst. 1981, 66, 249-254. (Pubitemid 11117626)
24. Vadhan-Raj, S.; Cordon-Cardo, C.; Carswell, E.; Mintzer, D.; Dantis, L.; Duteau, C.; Templeton, M.A.; Oettgen, H.F.; Old, L.J.; Houghton, A.N. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J. Clin. Oncol. 1988, 6, 1636-1648. (Pubitemid 19092402)
25. Nasi, M.L.; Meyers, M.; Livingston, P.O.; Houghton, A.N.; Chapman, P.B. Antimelanoma effects of r24, a monoclonal antibody against GD3 ganglioside. Melanoma Res. 1997, 7, S155-S162. (Pubitemid 27501641)
26. Kuberan, B.; Linhardt, R.J. Carbohydrate based vaccines. Curr. Org. Chem. 2000, 4, 635-677.
27. Filion, M.C.; Phillips, N.C. Pro-inflammatory activity of contaminating DNA in hyaluronic acid preparations. J. Pharm. Pharmacol. 2001, 53, 555-561. (Pubitemid 32396548)
28. Galonic, D.P.; Gin, D.Y. Chemical glycosylation in the synthesis of glycoconjugate antitumor vaccines. Nature 2007, 446, 1000-1007. (Pubitemid 46691044)
29. Hsu, C.-H.; Hung, S.-C.; Wu, C.-Y.; Wong, C.-H. Toward automated oligosaccharide synthesis. Angew. Chem. Int. Ed. 2011, 50, 11872-11923.
30. Wang, Z.; Huang, X. Strategies in oligosaccharide synthesis. In Comprehensive Glycoscience from Chemistry to Systems Biology; Kamerling, J. P., Ed.; Elsevier: Amsterdam, 2007, Vol. 1, 379-413.
31. Icart, L.P.; Fernandez-Santana, V.; Veloso, R.C.; Carmenate, T.; Sirois, S.; Roy, R.; Bencomo, V.V. T-cell immunity of carbohydrates. In Carbohydrate-Based Vaccines (ACS symposium series, 989); Roy, R., Ed.; American Chemical Society: Washington, D.C., 2008, 1-19.
32. Helling, F.; Shang, A.; Calves,M.; Zhang, S.; Ren, S.; Yu, R.K.; Oettgen, H.E.; Livingston, P.O. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 1994, 54, 197-203.
33. Livingston, P.O.; Ritter, G.; Srivastava, P.; Padavan, M.; Calves, M.J.; Oettgen, H.E.; Old, L.J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res. 1989, 49, 7045-7050. (Pubitemid 20016591)
34. Livingston, P.O.; Natoli, E.J.J.; Calves, M.J.; Stockert, E.; Oettgen, H.F. Old Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA 1987, 84, 2911-2915. (Pubitemid 17064748)
35. Vliegenthart, J.F.G. Carbohydrate based vaccines. FEBS Lett. 2006, 580, 2945-2950. (Pubitemid 43729166)
36. Freire, T.; Bay, S.; Vichier-Guerre, S.; Lo-Man, R.; Leclerc, C. Carbohydrate antigens: synthesis aspects and immunological applications in cancer. Mini-Rev. Med. Chem. 2006, 6, 1357-1373. (Pubitemid 44890543)
37. Roy, R. New trends in carbohydrate-based vaccines. Drug Disc. Today Technologies 2004, 1, 327-336. (Pubitemid 40197583)
38. Liakatos, A.; Kunz, H. Synthetic glycopeptides for the development of cancer vaccines. Curr. Opin. Mol. Therap. 2007, 9, 35-44. (Pubitemid 46438447)
39. Livingston, P.O.; Ragupathi, G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol. Immunother. 1997, 45, 10-19. (Pubitemid 27444465)
40. Germain, R.N. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994, 76, 287-299. (Pubitemid 24046691)
41. Dintzis, H.M.; Dintzis, R.Z.; Vogelstein, B. Molecular determinants of immunogenicity: the immuno model of immune response. Proc. Nat. Acad. Sci. USA 1976, 73, 3671-3675.
42. Denis, J.; Majeau, N.; Acosta-Ramirez, E.; Savard, C.; Bedard, M.-C.; Simard, S.; Lecours, K.; Bolduc, M.; Pare, C.; Willems, B.; Shoukry, N.; Tessier, P.; Lacasse, P.; Lamarre, A.; Lapointe, R.; Lopez Macias, C.; Leclerc, D. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology 2007, 363, 59-68. (Pubitemid 46695744)
43. Jegerlehner, A.; Storni, T.; Lipowsky, G.; Schmid, M.; Pumpens, P.; Bachmann, M.F. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur. J. Immunol. 2002, 32, 3305-3314. (Pubitemid 35414888)
44. Bachmann, M.F.; Hengartner, H.; Zinkernagel, R.M. T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. 1995, 25, 3445-3451. (Pubitemid 26004953)
45. Bachmann, M.F.; Zinkernagel, R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 1997, 15, 235-270. (Pubitemid 27169281)
46. Bachmann, M.F.; Rohrer, U.H.; Kundig, T.M.; Burki, K.; Hengartner, H.; Zinkernagel, R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262, 1448-1451. (Pubitemid 24035067)
47. Germain, R.N.; Margulies, D.H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 1993, 11, 403-450. (Pubitemid 23115014)
48. Haurum, J.S.;Arsequell, G.; Lellouch, A.C.; Wong, S.Y.; Dwek, R.A.; McMichael, A.J.; Elliott, T. Recognition of carbohydrate by major histocompatibility complex class Irestricted, glycopeptide-specific cytotoxic t lymphocytes. J. Exp. Med. 1994, 180, 739-44.
49. Abdel-Motal, U.M.; Berg, L.; Rosen, A.; Bengtsson, M.; Thorpe, C.J.; Kihlberg, J.; Dahmen, J.; Magnusson, G.; Karlsson, K.A.; Jondal, M. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur. J. Immunol. 1996, 26, 544-451.
50. Speir, J.A.; Abdel-Motal, U.M.; Jondal, M.; Wilson, I.A. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999, 10, 51-61. (Pubitemid 29077383)
51. Dengjel, J.; Rammensee, H.G.; Stevanovic, S. Glycan side chains on naturally presented MHC class II ligands. J. Mass Spectrom. 2005, 40, 100-104. (Pubitemid 40188986)
52. Dudler, T.; Altmann, F.; Carballido, J.M.; Blaser, K. Carbohydrate-dependent, HLA class II-restricted, human T cell response to the bee venom allergen phospholipase A2 in allergic patients. Eur. J. Immunol. 1995, 25, 538-542.
53. Ando, S.; Yu, R.K.; Scarsdale, J.N.; Kusunoki, S.; Prestegard, J.H. High resolution proton NMR studies of gangliosides. Structure of two types of GD3 lactones and their reactivity with monoclonal antibody R24. J. Biol. Chem. 1989, 264, 3478-3483. (Pubitemid 19063406)
54. Ritter, G.; Boosfeld, E.; Calves, M.J.; Oettgen, H.F.; Old, L.J.; Livingston, P.O. Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. Immunobiology 1990, 182, 32-43.
55. Ritter, G.; Boosfeld, E.; Adluri, R.; Calves, M.; Oettgen, H.F.; Old, L.J.; Livingston, P. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J. Cancer 1991, 48, 379-385.
56. Ragupathi, G.; Meyers, M.; Adluri, S.; Howard, L.; Musselli, C.; Livingston, P.O. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-klh conjugate plus immunological adjuvant QS-21. Int. J. Cancer 2000, 85, 659-666. (Pubitemid 30080479)
57. Kawashima, I.; Kotani, M.; Ozawa, H.; Suzuki, M.; Tai, T. Generation of monoclonal antibodies specific for ganglioside lactones: evidence of the expression of lactone on human melanoma cells. Int. J. Cancer 1994, 58, 263-268. (Pubitemid 24240106)
58. Maggio, B.;Ariga, T.; Yu, R.K. Ganglioside GD3 lactones: polar head group mediated control of the intermolecular organization. Biochemistry 1990, 29, 8729-8734. (Pubitemid 20302768)
59. Ding, K.; Rosen, A.; Ray, A.K.; Magnusson, G. Anti-GM3-lactam monoclonal antibodies of the IgG type recognize natural GM3-ganglioside lactone but not GM3-ganglioside. Glycoconjugate J. 1992, 9, 303-306. (Pubitemid 23113295)
60. Arcangeli, A.; Toma, L.; Contiero, L.; Crociani, O.; Legnani, L.; Lunghi, C.; Nesti, E.; Moneti, G.; Richichi, B.; Nativi, C. Stable GM3 lactone mimetic raises antibodies specific for the antigens expressed on melanoma cells. Bioconjugate Chem. 2010, 21, 1432-1438.
61. Kohla, G.; Stockfleth, E.; Schauer, R. Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin. Neurochem. Res. 2002, 27, 583-592.
62. Cheresh, D.A.; Reisfeld, R.A.; Varki, A.P. O-Acetylation of disialoganglioside GD3 by human melanoma cells creates a unique antigenic determinant. Science 1984, 225, 844-6. (Pubitemid 14058362)
63. Ritter, G.; Ritter-Boosfeld, E.; Adluri, R.; Calves, M.; Ren, S.; Yu, R.K.; Oettgen, H.F.; Old, L.J.; Livingston, P.O. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients withmalignant melanoma. Int. J. Cancer 1995, 62, 668-672.
64. Schauer, R. Achievements and challenges of sialic acid research. Glycoconjugate J. 2000, 17, 485-499. (Pubitemid 32480340)
65. Irie, A.; Koyama, S.; Kozutsumi, Y.; Kawasaki, T.; Suzuki, A. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 1998, 273, 15866-71. (Pubitemid 28298210)
66. Malykh, Y.N.; Schauer, R.; Shaw, L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001, 83, 623-634. (Pubitemid 32821226)
67. de Leon, J.; Fernandez, A.; Mesa, C.; Clavel, M.; Fernandez, L.E. Role of tumourassociated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol. Immunother. 2006, 55, 443-450. (Pubitemid 43076896)
68. Nakarai, H.; Chandler, P.J.; Kano, K.; Morton, D.L.; Irie, R.F. Hanganutziudeicher antigen as a possible target for immunotherapy of melanoma. Int.Arch. Allergy Appl. Immunol. 1990, 91, 323-328. (Pubitemid 20182325)
69. Fernandez, L.E.; Alonso, D.F.; Gomez, D.E.; Vazquez, A.M. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev. Vaccines 2003, 2, 817-823. (Pubitemid 37541567)
70. Osorio, M.; Gracia, E.; Rodriguez, E.; Saurez, G.;Arango Mdel, C.; Noris, E.; Torriella, A.; Joan, A.; Gomez, E.; Anasagasti, L.; Gonzalez, J.L.; Melgares Mde, L.; Torres, I.; Gonzalez, J.; Alonso, D.; Rengifo, E.; Carr, A.; Perez, R.; Fernandez, L.E. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a phase Ib/IIa study. Cancer Biol. Ther. 2008, 7, 488-495. (Pubitemid 351847021)
71. Wëwer, M.; Huang, F.; Chen, C.-C.; Yuan, X.; Tokuzaki, K.; Tomiyama, H.; Linhardt, R.J. Synthesis and evaluation of anticancer vaccine candidates, c-glycoside analogs of STn and PSA. In Chemical glycobiology; Chen, X., Halcomb, R.L., Wang, P.G., Eds.; American Chemical Society: Washington, D.C., 2008, 216-238.
72. Bundle, D.R.; Rich, J.R.; Jacques, S.; Yu, H.N.; Nitz, M.; Ling, C.-C. Thiooligosaccharide conjugate vaccines evoke antibodies specific for native antigens. Angew. Chem. Int. Ed. 2005, 44, 7725-7729. (Pubitemid 41759536)
73. Kuberan, B.; Sikkander, S.A.; Tomiyama, H.; Linhardt, R.J. Synthesis of a Cglycoside analogue of STn: an HIV-and tumor-associated antigen. Angew. Chem. Int. Ed. 2003, 42, 2073-2075. (Pubitemid 36604354)
74. Yang, F.; Zheng, X.J.; Huo, C.X.; Wang, Y.; Zhang, Y.; Ye, X.S. Enhancement of the immunogenicity of synthetic carbohydrate vaccines by chemical modifications of stn antigen. ACS Chem. Biol. 2011, 6, 252-259.
75. Hoffmann-R̈oder, A.; Kaiser, A.; Wagner, S.; Gaidzik, N.; Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Schmitt, E.; Kunz, H. Synthetic antitumor vaccines from tetanus toxoid conjugates of MUC1 glycopeptides with the Thomsen-Friedenreich antigen and a fluorine-substituted analogue. Angew. Chem. Int. Ed. 2010, 49, 8498-8503.
76. Kayser, H.; Zeitler, R.; Kannicht, C.; Grunow, D.; Nuck, R.; Reutter, W. Biosynthesis of a nonphysiological sialic acid in different rat organs, using N-propanoyl-Dhexosamines as precursors. J. Biol. Chem. 1992, 267, 16934-16938.
77. Lemieux, G.A.; Bertozzi, C.R. Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens. Chem. Biol. 2001, 8, 265-275. (Pubitemid 32296116)
78. Liu, T.; Guo, Z.; Yang, Q.; Sad, S.; Jennings, H.J. Biochemical engineering of surface a2-8 polysialic acid for immunotargeting tumor cells. J. Biol. Chem. 2000, 275, 32832-32836.
79. Zou, W.; Borrelli, S.; Gilbert, M.; Liu, T.; Pon, R.A.; Jennings, H.J. Bioengineering of surface GD3 ganglioside for immunotargeting human melanoma cells. J. Biol. Chem. 2004, 279, 25390-25399. (Pubitemid 38756796)
80. Pan, Y.; Chefalo, P.; Nagy, N.; Harding, C.; Guo, Z. Synthesis and immunological properties of N-modified GM3 antigens as therapeutic cancer vaccines. J. Med. Chem. 2005, 48, 875-883. (Pubitemid 40209110)
81. Chefalo, P.; Pan, Y.; Nagy, N.; Guo, Z.; Harding, C.V. Efficient metabolic engineering of GM3 on tumor cells by N-phenylacetyl-D-mannosamine. Biochemistry 2006, 45, 3733-3739.
82. Wang, Q.; Zhang, J.; Guo, Z. Efficient glycoengineering of GM3 on melanoma cell and monoclonal antibody-mediated selective killing of the glycoengineered cancer cell. Bioorg. Med. Chem. 2007, 15, 7561-7567. (Pubitemid 47575927)
83. Yu, S.; Wang, Q.; Zhang, J.; Wu, Q.; Guo, Z. Synthesis and evaluation of protein conjugates of GM3 derivatives carrying modified sialic acids as highly immunogenic cancer vaccine candidates. Medchemcomm 2011, 2, 524-530.
84. Wang, Q.; Guo, Z. Synthetic and immunological studies of STn derivatives carrying 5-N-(p-substituted phenylacetyl)sialic acid for the development of effective cancer vaccines. ACS Med. Chem. Lett. 2011, 2, 373-378.
85. Lansteiner, K.; Chase, M.W. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc. Soc. Exp. Biol. Med 1942, 49, 688-690.
86. Bremer, E.G.; Levery, S.B.; Sonnino, S.; Ghidoni, R.; Canevari, S.; Kannagi, R.; Hakomori, S. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland. J. Biol. Chem. 1984, 259, 14773-14777. (Pubitemid 15222206)
87. Zhang, S.; Cordon-Cardo, C.; Zhang, H.S.; Reuter, V.E.; Adluri, S.; Hamilton, W.B.; Lloyd, K.O.; Livingston, P.O. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 1997, 73, 42-49. (Pubitemid 27445989)
88. Ragupathi, G.; Park, T.K.; Zhang, S.; Kim, I.J.; Graber, L.; Adluri, S.; Lloyd, K.O.; Danishefsky, S.J.; Livingston, P.O. Immunization of mice with a fully synthetic Globo H antigen results in antibodies against human cancer cells: a combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew. Chem. Int. Ed. 1997, 36, 125-128.
89. Park, T.Y.; Kim, I.J.; Hu, S.; Bilodeau, M.T.; Randolph, J.T.; Kwon, O.; Danishefsky, S.J. Total synthesis and proof of structure of a human breast tumor (Globo H) antigen. J. Am. Chem. Soc. 1996, 118, 11488-11500. (Pubitemid 26399680)
90. Ragupathi, G.; Slovin, S.F.; Adluri, S.; Sames, D.; Kim, I.J.; Kim, H.M.; Spassova, M.; Bornmann,W.G.; Lloyd, K.O.; Scher, H.I.; Livingston, P.O.; Danishefsky, S.J. A fully synthetic Globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angew. Chem. Int. Ed. 1999, 38, 563-566. (Pubitemid 29095523)
91. Slovin, S.F.; Ragupathi, G.; Adluri, S.; Ungers, G.; Terry, K.; Kim, S.; Spassova, M.; Bornmann, W.G.; Fazzari, M.; Dantis, L.; Olkiewicz, K.; Lloyd, K.O.; Livingston, P.O.; Danishefsky, S.J.; Scher, H.I. Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic Globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA 1999, 96, 5710-5715. (Pubitemid 29234683)
92. Gilewski, T.; Ragupathi, G.; Bhuta, S.; Williams, L.J.; Musselli, C.; Zhang, X.-F.; Bencsath, K.P.; Panageas, K.S.; Chin, J.; Hudis, C.A.; Norton, L.; Houghton, A.N.; Livingston, P.O.; Danishefsky, S.J. Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: a phase I trial. Proc. Nat. Acad. Sci. USA 2001, 98, 3270-3275. (Pubitemid 32220835)
93. Livingston, P.; Zhang, S.; Adluri, S.; Yao, T.J.; Graeber, L.; Ragupathi, G.; Helling, F.; Fleisher, M. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol. Immunother. 1997, 43, 324-330. (Pubitemid 27102217)
94. Kirkwood, J.M.; Ibrahim, J.G.; Sosman, J.A.; Sondak, V.K.; Agarwala, S.S.; Ernstoff, M.S.; Rao, U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001, 19, 2370-2380. (Pubitemid 32391207)
95. Eggermont, A.M.; Suciu, S.; Rutkowski, P.; Marsden, J.; Testori, A.; Corrie, P.; Aamdal, S.; Ascierto, P.A.; Spatz, A.; Group, E.M. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J. Clin. Oncol. 2010, 28(15), suppl 8505.
96. Itzkowitz, S.H. Blood group-related carbohydrate antigen expression in malignant and premalignant colonic neoplasms. J. Cell Biochem. Suppl. 1992, 16G, 97-101.
97. Fukushima, K. Expression of Lewis(x), sialylated Lewis(x), Lewis(a), and sialylated Lewis(a) antigens in human lung carcinoma. Tohoku J. Exp. Med. 1991, 163, 17-30.
98. Larrain, M.I.; Demichelis, S.; Crespo, M.; Lacunza, E.; Barbera, A.; Creton, A.; Terrier, F.; Segal-Eiras, A.; Croce, M.V. Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with mucin 1 (MUC1). J. Exp. Clin. Cancer Res. 2009, 28, 121.
99. Myers, R.B.; Srivastava, S.; Grizzle, W.E. Lewis y antigen as detected by the monoclonal antibody br96 is expressed strongly in prostatic adenocarcinoma. J. Urol. 1995, 153, 1572-1574.
100. Yin, B.W.; Finstad, C.L.; Kitamura, K.; Federici, M.G.; Welshinger, M.; Kudryashov, V.; Hoskins, W.J.; Welt, S.; Lloyd, K.O. Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer. Int. J. Cancer 1996, 65, 406-412.
101. Federici, M.F.; Kudryashov, V.; Saigo, P.E.; Finstad, C.L.; Lloyd, K.O. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int. J. Cancer 1999, 81, 193-198. (Pubitemid 29144746)
102. Buskas, T.; Li, Y.; Boons, G.-J. The immunogenicity of the tumor-associated antigen lewisy may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chem. Eur. J. 2004, 10, 3517-3524.
103. Danishefsky, S.J.; Behar, V.; Randolph, J.T.; Lloyd, K. Application of the glycal assembly method to the concise synthesis of neoglycoconjugates of Ley and Leb blood group determinants and of H-type I and H-type II oligosaccharides. J. Am. Chem. Soc. 1995, 117, 5701-5711.
104. Kudryashov, V.; Kim, H.M.; Ragupathi, G.; Danishefsky, S.J.; Livingston, P.O.; Lloyd, K.O. Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines. Cancer Immunol. Immunother. 1998, 45, 281-286. (Pubitemid 28088236)
105. Sabbatini, P.J.; Kudryashov, V.; Ragupathi, G.; Danishefsky, S.J.; Livingston, P.O.; Bornmann, W.; Spassova, M.; Zatorski, A.; Spriggs, D.; Aghajanian, C.; Soignet, S.; Peyton, M.; O'Flaherty, C.; Curtin, J.; Lloyd, K.O. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int. J. Cancer 2000, 87, 79-85. (Pubitemid 30368419)
106. Buskas, T.; Li, Y.; Boons, G.J. Synthesis of a dimeric Lewis antigen and the evaluation of the epitope specificity of antibodies elicited in mice. Chem. Eur. J. 2005, 11, 5457-5467. (Pubitemid 41285100)
107. Kim, Y.S.; Yuan, M.; Itzkowitz, S.H.; Sun, Q.B.; Kaizu, T.; Palekar, A.; Trump, B.F.; Hakomori, S. Expression of Ley and extended Ley blood group-related antigens in human malignant, premalignant, and nonmalignant colonic tissues. Cancer Res. 1986, 46, 5985-5992. (Pubitemid 17178016)
108. Ragupathi, G.; Deshpande, P.P.; Coltart, D.M.; Kim, H.M.; Williams, L.J.; Danishefsky, S.J.; Livingston, P.O. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies. Int. J. Cancer 2002, 99, 207-212. (Pubitemid 34309477)
109. Macher, B.A.; Pacuszka, T.; Mullin, B.R.; Sweeley, C.C.; Brady, R.O.; Fishman, P.H. Isolation and identification of a fucose-containing ganglioside from bovine thyroid gland. Biochim. Biophys. Acta. 1979, 588, 35-43. (Pubitemid 10188247)
110. Nilsson, O.; Brezicka, F.T.; Holmgren, J.; Sorenson, S.; Svennerholm, L.; Yngvason, F.; Lindholm, L. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Cancer Res. 1986, 46, 1403-1407. (Pubitemid 16048287)
111. Cappello, S.; Liu, N.X.; Musselli, C.; Brezicka, F.T.; Livingston, P.O.; Ragupathi, G. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells. Cancer Immunol. Immunother. 1999, 48, 483-492.
112. Dickler, M.N.; Ragupathi, G.; Liu, N.X.; Musselli, C.; Martino, D.J.; Miller, V.A.; Kris, M.G.; Brezicka, F.T.; Livingston, P.O.; Grant, S.C. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 1999, 5, 2773-2779. (Pubitemid 29493951)
113. Krug, L.M.; Ragupathi, G.; Hood, C.; Kris, M.G.; Miller, V.A.; Allen, J.R.; Keding, S.J.; Danishefsky, S.J.; Gomez, J.; Tyson, L.; Pizzo, B.; Baez, V.; Livingston, P.O. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 2004, 10, 6094-6100. (Pubitemid 39287514)
114. Gendler, S.J.; Lancaster, C.A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E.N.; Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 1990, 265, 15286-15293.
115. Hanisch, F.G.; Ninkovic, T. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Pept. Sci. 2006, 7, 307-315.
116. Gaidzik, N.; Kaiser, A.; Kowalczyk, D.; Westerlind, U.; Gerlitzki, B.; Sinn, H.P.; Schmitt, E.; Kunz, H. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues. Angew. Chem. Int. Ed. 2011, 50, 9977-9981 and references cited therein.
117. Sorensen, A.L.; Reis, C.A.; Tarp, M.A.; Mandel, U.; Ramachandran, K.; Sankaranarayanan, V.; Schwientek, T.; Graham, R.; Taylor-Papadimitriou, J.; Hollingsworth, M.A.; Burchell, J.; Clausen, H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16, 96-107. (Pubitemid 43125966)
118. Kagan, E.; Ragupathi, G.; Yi, S.S.; Reis, C.A.; Gildersleeve, J.; Kahne, D.; Clausen, H.; Danishefsky, S.J.; Livingston, P.O. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 2005, 54, 424-430. (Pubitemid 40543682)
119. Julien, S.; Picco, G.; Sewell, R.; Vercoutter-Edouart, A.S.; Tarp, M.; Miles, D.; Clausen, H.; Taylor-Papadimitriou, J.; Burchell, J.M. Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model. Br. J. Cancer 2009, 100, 1746-1754.
120. Slovin, S.F.; Ragupathi, G.; Musselli, C.; Olkiewicz, K.; Verbel, D.; Kuduk, S.D.; Schwarz, J.B.; Sames, D.; Danishefsky, S.; Livingston, P.O.; Scher, H.I. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with a-N-acetylgalactosamine-O-serine/ threonine conjugate vaccine. J. Clin. Oncol. 2003, 21, 4292-4298. (Pubitemid 46621804)
121. Ragupathi, G.; Howard, L.; Cappello, S.; Koganty, R.R.; Qiu, D.; Longenecker, B.M.; Reddish, M.A.; Lloyd, K.O.; Livingston, P.O. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol. Immunother. 1999, 48, 1-8. (Pubitemid 29197237)
122. (c) Slovin, S.F.; Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H.I. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 2005, 54, 694-702. (Pubitemid 40884166)
123. (c)Ragupathi, G.; Koide, F.; Sathyan, N.; Kagan, E.; Spassova, M.; Bornmann, W.; Gregor, P.; Reis, C.A.; Clausen, H.; Danishefsky, S.J.; Livingston, P.O. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLHconjugate vaccine against epithelial cancers. Cancer Immunol. Immunother. 2003, 52, 608-616. (Pubitemid 37268193)
124. Sabbatini, P.J.; Ragupathi, G.; Hood, C.; Aghajanian, C.A.; Juretzka, M.; Iasonos, A.; Hensley, M.L.; Spassova, M.K.; Ouerfelli, O.; Spriggs, D.R.; Tew, W.P.; Konner, J.; Clausen, H.; Abu Rustum, N.; Dansihefsky, S.J.; Livingston, P.O. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 2007, 13, 4170-4177. (Pubitemid 47105980)
125. Ragupathi, G.; Koide, F.; Livingston, P.O.; Cho, Y.S.; Endo, A.;Wan, Q.; Spassova, M.K.; Keding, S.J.; Allen, J.; Ouerfelli, O.; Wilson, R.M.; Danishefsky, S.J. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J. Am. Chem. Soc. 2006, 128, 2715-2725. (Pubitemid 43327950)
126. Zhu, J.; Wan, Q.; Ragupathi, G.; George, C.M.; Livingston, P.O.; Danishefsky, S.J. Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains. J. Am. Chem. Soc. 2009, 131, 4151-4158.
127. Lee, D.; Danishefsky, S.J. "Biologic" Level structures through chemistry: a total synthesis of a unimolecular pentavalent MUC1 glycopeptide construct. Tetrahedron Lett 2009, 50, 2167-2170.
128. Goldman, B.; DeFrancesco, L. The cancer vaccine roller coaster. Nature Biotech. 2009, 27, 129-139.
129. Geyer, H.; Wuhrer, M.; Kurokawa, T.; Geyer, R. Characterization of keyhole limpet hemocyanin (KLH) glycans sharing a carbohydrate epitope with schistosoma mansoni glycoconjugates. Micron 2004, 35, 105-106. (Pubitemid 38214834)
130. Roldao, A.; Mellado, M.C.; Castilho, L.R.; Carrondo, M.J.; Alves, P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9, 1149-1176.
131. Lin, T.; Chen, Z.; Usha, R.; Stauffacher, C.V.; Dai, J.-B.; Schmidt, T.; Johnson, J.E. The refined crystal structure of cowpea mosaic virus at 2.8 °A resolution. Virology 1999, 265, 20-34. (Pubitemid 30012382)
132. Miermont, A.; Barnhill, H.; Strable, E.; Lu, X.; Wall, K.A.; Wang, Q.; Finn, M.G.; Huang, X. Cowpea mosaic virus capsid: a promising carrier for the development of carbohydrate based antitumor vaccines. Chem. Eur. J. 2008, 14, 4939-4947.
133. Gupta, S.S.; Kuzelka, J.; Singh, P.; Lewis, W.G.; Manchester, M.; Finn, M.G. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjugate Chem. 2005, 16, 1572-1579. (Pubitemid 41681525)
134. Chatterji, A.; Ochoa, W.; Shamieh, L.; Salakian, S.P.; Wong, S.M.; Clinton, G.; Ghosh, P.; Lin, T.; Johnson, J.E. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjugate Chem. 2004, 15, 807-813. (Pubitemid 38981955)
135. Chatterji, A.; Ochoa, W.F.; Paine, M.; Ratna, B.R.; Johnson, J.E.; Lin, T. New addresses on an addressable virus nanoblock: uniquely reactive lys residues on cowpea mosaic virus. Chem. Biol. 2004, 11, 855-863. (Pubitemid 38836901)
136. Kaltgrad, E.; Sen Gupta, S.; Punna, S.; Huang, C.Y.; Chang, A.;Wong, C.H.; Finn, M.G.; Blixt, O. Anti-carbohydrate antibodies elicited by polyvalent display on a viral scaffold. ChemBiochem 2007, 8, 1455-1462. (Pubitemid 47300340)
137. Cobb, B.A.; Kasper, D.L. Zwitterionic capsular polysaccharides: the new MHC II-dependent antigens. Cell Microbiol. 2005, 7, 1398-1403. (Pubitemid 41335244)
138. Tzianabos, A.; Wang, J.Y.; Kasper, D.L. Biological chemistry of immunomodulation by zwitterionic polysaccharides. Carbohydr. Res. 2003, 338, 2531-2538. (Pubitemid 37509952)
139. Wang, Q.; McLoughlin, R.M.; Cobb, B.A.; Charrel-Dennis, M.; Zaleski, K.J.; Golenbock, D.; Tzianabos, A.O.; Kasper, D.L. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J. Exp. Med. 2006, 203, 2853-2863. (Pubitemid 46026163)
140. De Silva, R.A.;Wang, Q.; Chidley, T.; Appulage, D.K.; Andreana, P.R. Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PSA1 conjugates. J. Am. Chem. Soc. 2009, 131, 9622-9623.
141. Herzenberg, L.A.; Tokuhisa, T.; Herzenberg, L.A. Carrier-priming leads to hapten-specific suppression. Nature 1980, 285, 664-667. (Pubitemid 10058188)
142. Schutze, M.P.; Leclerc, C.; Jolivet, M.; Audibert, F.; Chedid, L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 1985, 135, 2319-2322. (Pubitemid 16217114)
143. Posnett, D.N.; McGrath, H.; Tam, J.P. A novel method for producing anti-peptide antibodies. Production of site-specific antibodies to the T cell antigen receptor betachain. J. Biol. Chem. 1988, 263, 1719-1725. (Pubitemid 18052120)
144. Bay, S.; Lo-Man, R.; Osinaga, E.; Nakada, H.; Leclerc, C.; Cantacuzene, D. Preparation of a multiple antigen glycopeptide (MAG) carrying the Tn antigen. A possible approach to a synthetic carbohydrate vaccine. J. Pept. Res. 1997, 49, 620-625. (Pubitemid 27335008)
145. Lo-Man, R.; Vichier-Guerre, S.; Bay, S.; Deriaud, E.; Cantacuzene, D.; Leclerc, C. Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J. Immunol. 2001, 166, 2849-2854. (Pubitemid 32173527)
146. Lo-Man, R.; Vichier-Guerre, S.; Perraut, R.; Deriaud, E.; Huteau, V.; BenMohamed, L.; Diop, O.M.; Livingston, P.O.; Bay, S.; Leclerc, C. A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 2004, 64, 4987-4994. (Pubitemid 38924547)
147. Freire, T.; Zhang, X.; Deriaud, E.; Ganneau, C.; Vichier-Guerre, S.; Azria, E.; Launay, O.; Lo-Man, R.; Bay, S.; Leclerc, C. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood 2010, 116, 3526-3536.
148. Deres, K.; Schild, H.;Wiesmuller, K.H.; Jung, G.; Rammensee, H.G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989, 342, 561-564. (Pubitemid 20005823)
149. Toyokuni, T.; Dean, B.; Cai, S.; Boivin, D.; Hakomori, S.; Singhal, A.K. Synthetic vaccines: synthesis of a dimeric Tn antigen-lipopeptide conjugate that elicits immune responses against Tn-expressing glycoproteins. J. Am. Chem. Soc. 1994, 116, 395-396.
150. Wang, Q.; Zhou, Z.; Tang, S.; Guo, Z. Carbohydrate-monophosphoryl lipid a conjugatesare fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse. ACS Chem. Biol. 2012, published online. DOI: 10.1021/cb200358r.
151. Buskas, T.; Ingale, S.; Boons, G.-J. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen. Angew. Chem. Int. Ed. 2005, 44, 5985-5988. (Pubitemid 41345916)
152. Ingale, S.; Wolfert, M.A.; Gaekwad, J.; Buskas, T.; Boons, G.-J. Robust immune responses elicited by a fully synthetic three-component vaccine. Nature Chem. Biol. 2007, 3, 663-667. (Pubitemid 47417705)
153. Ingale, S.; Wolfert, M.A.; Buskas, T.; Boons, G.-J. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. ChemBiochem 2009, 10, 455-463.
154. Sarkar, S.; Lombardo, S.A.; Herner, D.N.; Talan, R.S.; Wall, K.A.; Sucheck, S.J. Synthesis of a single molecule L-rhamnose-containing three component vaccine and evaluation of antigenicity in the presence of anti-L-rhamnose antibodies. J. Am. Chem. Soc. 2010, 132, 17236-17246.
155. Kaiser, A.; Gaidzik, N.; Becker, T.; Menge, C.; Groh, K.; Cai, H.; Li, Y.M.; Gerlitzki, B.; Schmitt, E.; Kunz, H. Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. Angew. Chem. Int. Ed. 2010, 49, 3688-3692.
156. Wilkinson, B.L.; Malins, L.R.; Chun, C.K.; Payne, R.J. Synthesis of MUC1-lipopeptide chimeras. Chem. Commun. 2010, 46, 6249-6251.
157. Wilkinson, B.L.; Day, S.; Malins, L.R.; Apostolopoulos, V.; Payne, R.J. Selfadjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew. Chem. Int. Ed. 2011, 50, 1635-1639.
158. Renaudet, O.; BenMohamed, L.; Dasgupta, G.; Bettahi, I.; Dumy, P. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 2008, 3, 737-741.
159. Bettahi, I.; Dasgupta, G.; Renaudet, O.; Chentoufi, A.A.; Zhang, X.; Carpenter, D.; Yoon, S.; Dumy, P.; BenMohamed, L. Antitumor activity of a self-adjuvanting glycolipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol. Immunother. 2009, 58, 187-200.
160. Renaudet, O.; Dasgupta, G.; Bettahi, I.; Shi, A.; Nesburn, A.B.; Dumy, P.; Ben-Mohamed, L. Linear and branched glyco-lipopeptide vaccines follow distinct crosspresentation pathways and generate different magnitudes of antitumor immunity. PLoS One 2010, 5, e11216.